natgillin/translations-raw huggingface dataset:
The same recommendations for renal function apply to elderly patients as to all patients (see sections 4.2, 4.4, 4.8 and 5.1). 
Za starejše bolnike veljajo enaka priporočila glede delovanja ledvic kot za ostale bolnike (glejte poglavja 4.2, 4.4, 4.8 in 5.1).
Cardiovascular death, MI and stroke were observed with a hazard ratio of 0.77 (95% CI: 0.54, 1.10). 
Kardiovaskularna smrt, MI in možganska kap so bile opažene z vrednostjo razmerja ogroženosti 0,77 (95 % IZ: 0,54, 1,10).
Forxiga works by removing excess sugar from your body via your urine. 
Zdravilo Forxiga deluje tako, da odstranjuje odvečni sladkor iz vašega telesa z urinom.
Other medicines and Forxiga 
Druga zdravila in zdravilo Forxiga
If you take more Forxiga than you should 
Če ste vzeli večji odmerek zdravila Forxiga, kot bi smeli
Use in patients treated with pioglitazone 
Uporaba pri bolnikih, zdravljenih s pioglitazonom
Diabetic ketoacidosis 
Diabetična ketoacidoza
Volume depletion includes, e.g. the predefined preferred terms: dehydration, hypovolaemia, hypotension. 
Pomanjkanje volumna vključuje, npr. vnaprej definirane prednostne izraze: dehidracija, hipovolemija, hipotenzija.
Dapagliflozin does not inhibit other glucose transporters important for glucose transport into peripheral tissues and is > 1,400 times more selective for SGLT2 versus SGLT1, the major transporter in the gut responsible for glucose absorption. 
Dapagliflozin ne zavira drugih prenašalcev glukoze, pomembnih za prenos glukoze v periferna tkiva, in je > 1.400-krat bolj selektiven za SGLT2 kot za SGLT1, tj. glavnega prenašalca, odgovornega za absorpcijo glukoze v črevesu.
• This medicine does not require any special storage conditions. 
• Za shranjevanje zdravila niso potrebna posebna navodila.
Gender The mean dapagliflozin AUCss in females was estimated to be about 22% higher than in males. 
Spol Ocenjeno je, da je povprečna AUCss dapagliflozina pri ženskah približno 22 % večja kot pri moških.
• if you have a kidney problem - your doctor may ask you to take a different medicine. 
• če imate težave z ledvicami - zdravnik vam bo morda naročil, da vzamete drugo zdravilo.
More information is given below in Other medicines and Forxiga. 
Več informacij je na voljo v nadaljevanju v poglavju "Druga zdravila in zdravilo Forxiga".
Elderly patients are more likely to have impaired renal function, and/or to be treated with anti-hypertensive medicinal products that may cause changes in renal function such as angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin II type 1 receptor blockers (ARB). 
Pri starejših bolnikih obstaja večja verjetnost prisotnosti poslabšanega delovanja ledvic in/ali, zdravljenja z antihipertenzivnimi zdravili, ki lahko povzročijo spremembe v delovanju ledvic, kot so zaviralci angiotenzinske konvertaze (ACE-I - angiotensin-converting enzyme inhibitors) in antagonisti angiotenzina II tipa I (ARB - angiotensin II type 1 receptor blockers).
Your doctor may prescribe Forxiga together with other medicine(s) to lower the amount of sugar in your blood. 
Zdravnik vam lahko zdravilo Forxiga predpiše skupaj s kakšnimi drugimi zdravili za zmanjšanje količine sladkorja v vaši krvi.
• if you have “type 1 diabetes” - the type that usually starts when you are young, and your body does not produce any insulin. 
• če imate "sladkorno bolezen tipa 1" - to je oblika sladkorne bolezni, ki se običajno pojavi v mladosti in pri kateri telo ne izdeluje insulina.
Forxiga is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control as: 
Zdravilo Forxiga je indicirano pri odraslih, starih 18 let in več, s sladkorno boleznijo tipa 2 za izboljšanje urejenosti glikemije kot:
Combination of a single dose of dapagliflozin 20 mg and simvastatin (a CYP3A4 substrate) resulted in a 19% increase in AUC of simvastatin and 31% increase in AUC of simvastatin acid. 
Kombinacija enkratnega odmerka 20 mg dapagliflozina in simvastatina (substrata CYP3A4) je povzročila 19 % povečanje AUC simvastatina in 31 % povečanje AUC simvastatinske kisline.
In in vitro studies, dapagliflozin neither inhibited cytochrome P450 (CYP) 1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, nor induced CYP1A2, CYP2B6 or CYP3A4. 
V študijah in vitro dapagliflozin ni niti zaviral citokroma P450 (CYP) 1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, niti induciral CYP1A2, CYP2B6 ali CYP3A4.
SGLT2 is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. 
SGLT2 je poglavitni prenašalec, odgovoren za reabsorpcijo glukoze iz glomerularnega filtrata nazaj v krvni obtok.
To control your diabetes, you still need to keep to diet and exercise, even when you are taking this medicine. 
Za obvladovanje sladkorne bolezni je treba upoštevati dieto in biti telesno dejaven, četudi jemljete to zdravilo.
• You can take the tablet at any time of the day. 
• Tableto lahko vzamete kadar koli tekom dneva, vendar jo poskusite vzeti vsak dan ob približno istem času.
The primary end point was the time-to-first event of one of the following outcomes: cardiovascular death, stroke, myocardial infarction (MI) or hospitalisation for unstable angina. 
Primarni opazovani dogodek je bil čas do prvega od naslednjih izidov: kardiovaskularne smrti, možganske kapi, miokardnega infarkta (MI) ali sprejema v bolnišnico zaradi nestabilne angine pektoris.
• changes in the amount of cholesterol or fats in your blood (shown in tests) 
• spremenjena količina holesterola ali maščob v vaši krvi (to se pokaže v preiskavah)
Available epidemiological data for pioglitazone suggest a small increased risk of bladder cancer in diabetic patients treated with pioglitazone. 
Epidemiološki podatki za pioglitazon, ki so na voljo, namigujejo na majhno povečanje tveganja za raka sečnega mehurja pri bolnikih s sladkorno boleznijo, ki se zdravijo s pioglitazonom.
What Forxiga is and what it is used for What you need to know before you take Forxiga How to take Forxiga 
Kaj je zdravilo Forxiga in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Forxiga Kako jemati zdravilo Forxiga Možni neželeni učinki
The absolute oral bioavailability of dapagliflozin following the administration of a 10 mg dose is 78%. 
Absolutna peroralna biološka uporabnost dapagliflozina po dajanju odmerka 10 mg je 78 %.
Patients with baseline HbA1c ≥ 9% 
Bolniki z izhodiščno vrednostjo HbA1c ≥ 9 %
Tell your doctor before you start taking Forxiga if you have any of these signs. 
Obvestite zdravnika pred začetkom jemanja zdravila Forxiga, če se je pri vas pojavil kateri koli izmed naštetih znakov.
For patients receiving dapagliflozin, in case of intercurrent conditions that may lead to volume depletion, careful monitoring of volume status (e.g. physical examination, blood pressure measurements, laboratory tests including haematocrit) and electrolytes is recommended. 
Pri bolnikih, ki prejemajo dapagliflozin, v primeru sočasno prisotnih stanj, ki lahko povzročijo pomanjkanje volumna, je priporočljivo skrbno spremljanje statusa volumna (npr. fizični pregled, meritve krvnega tlaka, laboratorijske preiskave, vključno s hematokritom) in elektrolitov.
In the clinical program, 34.4% of subjects had a history of cardiovascular disease (excluding hypertension) at baseline and 67.9% had hypertension. 
V kliničnem programu je imelo izhodiščno anamnezo kardiovaskularne bolezni (izključujoč hipertenzijo) 34,4 % preiskovancev in 67,9 % jih je imelo hipertenzijo.
Available pharmacodynamic/toxicological data in animals have shown excretion of dapagliflozin/metabolites in milk, as well as pharmacologically-mediated effects in nursing offspring (see section 5.3). 
Farmakodinamični in toksikološki podatki za živali, ki so na voljo, kažejo izločanje dapagliflozina/presnovkov v mleko kakor tudi farmakološke učinke pri dojenih mladičih (glejte poglavje 5.3).
Maximum dapagliflozin plasma concentrations (Cmax) were usually attained within 2 hours after administration in the fasted state. 
Največja koncentracija dapagliflozina v plazmi (Cmax) je običajno dosežena v 2 urah po dajanju na tešče.
Dapagliflozin is a highly potent (Ki: 0.55 nM), selective and reversible inhibitor of sodium-glucose co-transporter 2 (SGLT2). 
Dapagliflozin je zelo močan (Ki: 0,55 nM), selektivni in reverzibilni zaviralec natrij-glukoznega koprenašalca 2 (SGLT2 - sodium glucose co-transporter 2).
• if you often get infections of the urinary tract. 
• če se vam pogosto pojavljajo okužbe sečil.
Difference from placebo c 
Razlika glede na placebo c
If any of the above applies to you (or you are not sure), talk to your doctor, pharmacist or nurse before taking Forxiga. 
Če kaj od naštetega velja za vas (ali če ste negotovi), se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro, preden vzamete zdravilo Forxiga.
• thirst 
• žeja
Administration with a high-fat meal decreased dapagliflozin Cmax by up to 50% and prolonged Tmax by approximately 1 hour, but did not alter AUC as compared with the fasted state. 
Dajanje zelo mastnega obroka je zmanjšala Cmax dapagliflozina za do 50 % in podaljšala tmax za približno 1 uro, ni pa spremenila AUC v primerjavi s stanjem na tešče.
Caution should be exercised in patients for whom a dapagliflozin-induced drop in blood pressure could pose a risk, such as patients with known cardiovascular disease, patients on anti-hypertensive therapy with a history of hypotension or elderly patients. 
Previdnost je potrebna pri bolnikih, pri katerih bi z dapagliflozinom povzročen padec krvnega tlaka lahko pomenil tveganje, npr. pri bolnikih z znano srčno-žilno boleznijo, bolnikih, ki se zdravijo z antihipertenzivi in imajo hipotenzijo v anamnezi ali pri starejših bolnikih.
These subjects had detectable glucose in the urine for a dose-related period of time (at least 5 days for the 500 mg dose), with no reports of dehydration, hypotension or electrolyte imbalance, and with no clinically meaningful effect on QTc interval. 
Ti preiskovanci so imeli v obdobju, ki je bilo odvisno od odmerka (vsaj 5 dni po odmerku 500 mg), zaznavno glukozo v urinu, brez poročil o dehidraciji, hipotenziji ali neravnovesju elektrolitov in brez klinično pomembnega vpliva na interval QTc.
The hazard ratio comparing dapagliflozin to comparator was 0.79 (95% Confidence interval [CI]: 0.58, 1.07), indicating that in this analysis Forxiga is not associated with an increase in cardiovascular risk in patients with type 2 diabetes mellitus. 
Razmerje ogroženosti z dapagliflozinom v primerjavi s primerjalnim zdravilom je bilo 0,79 (95 % interval zaupanja [IZ]: 0,58; 1,07), kar nakazuje, da v tej analizi zdravilo Forxiga ni bilo povezano s povečanjem kardiovaskularnega tveganja pri bolnikih s sladkorno boleznijo tipa 2.
While a causal relationship between dapagliflozin and bladder cancer is unlikely (see sections 4.8 and 5.3), as a precautionary measure, dapagliflozin is not recommended for use in patients concomitantly treated with pioglitazone. 
Medtem ko vzročna povezanost med dapagliflozinom in rakom sečnega mehurja ni verjetna (glejte poglavja 4.8 in 5.3), pa kot previdnosti ukrep, uporaba dapagliflozina pri bolnikih, ki se sočasno zdravijo s pioglitazonom, ni priporočljiva.
These findings were associated with dose-related increases in kidney weight and macroscopic kidney enlargement observed at all doses. 
Ti izsledki so bili povezani s povečanjem mase ledvic, ki je bilo povezano z odmerkom, in makroskopskim povečanjem ledvic, opaznim pri vseh odmerkih.
Post-prandial glucose 
Postprandialna glukoza
Elderly patients may be at a greater risk for volume depletion and are more likely to be treated with diuretics. 
Pri starejših bolnikih obstaja večje tveganje za pomanjkanje volumna in večja verjetnost, da se zdravijo z diuretiki.
Therefore, dapagliflozin is not expected to alter the metabolic clearance of coadministered medicinal products that are metabolised by these enzymes. 
Zato ni pričakovati, da bi dapagliflozin spremenil presnovni očistek sočasno uporabljenih zdravil, ki jih presnavljajo ti encimi.
Before initiating dapagliflozin, factors in the patient history that may predispose to ketoacidosis should be considered. 
Pred uvedbo dapagliflozina je treba v bolnikovi anamnezi oceniti dejavnike, ki bi lahko povečali nagnjenost h ketoacidozi.
There were no clinically relevant differences in systemic exposures between White, Black or Asian races. 
Rasa Sistemska izpostavljenost se med belsko, črnsko in azijsko raso klinično ni pomembno razlikovala.
14 film-coated tablets 28 film-coated tablets 30x1 film-coated tablets 90x1 film-coated tablets 98 film-coated tablets 
14 filmsko obloženih tablet 28 filmsko obloženih tablet 30 x 1 filmsko obložena tableta 90 x 1 filmsko obložena tableta 98 filmsko obloženih tablet
Your doctor may decide to temporarily or permanently stop your treatment with Forxiga. 
Zdravnik se bo morda odločil, da vam zdravljenje z zdravilom Forxiga začasno prekine ali trajno konča.
In combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations). 
V kombinaciji z drugimi zdravili za zmanjševanje vrednosti glukoze krvi, vključno z insulinom, kadar slednja, skupaj z dieto in telesno dejavnostjo, ne dosežejo ustrezne urejenosti glikemije (glejte poglavja 4.4, 4.5 in 5.1 za podatke o različnih kombinacijah).
Restarting SGLT2 inhibitor treatment in patients with previous DKA while on SGLT2 inhibitor treatment is not recommended, unless another clear precipitating factor is identified and resolved. 
Bolnikom, ki se jim je kdaj med zdravljenjem z zaviralcem SGLT2 pojavila DKA, zaviralca SGLT2 ni priporočljivo znova uvesti, razen če je ugotovljen in odpravljen kakšen drug nedvomen sprožilni dejavnik.
These infections were more frequent in females (8.4% and 1.2% for dapagliflozin and placebo, respectively), and subjects with a prior history were more likely to have a recurrent infection. 
O teh okužbah so pogosteje poročali pri ženskah (8,4 % za dapagliflozin in 1,2 % za placebo) ter pri preiskovancih s predhodno anamnezo in torej večjo verjetnostjo za pojav ponovne okužbe.
The risk of developing diabetic ketoacidosis may be increased with prolonged fasting, excessive alcohol consumption, dehydration, sudden reductions in insulin dose, or a higher need of insulin due to major surgery or serious illness. 
Tveganje za nastanek diabetične ketoacidoze je lahko večje v primeru dolgotrajnejšega stradanja, prekomernega uživanja alkoholnih pijač, dehidracije, nenadnega zmanjšanja odmerka insulina ali povečane potrebe po insulinu zaradi večje operacije ali resne bolezni.
These changes are not considered to be clinically meaningful. 
Te spremembe ne veljajo za klinično pomembne.
The most commonly reported adverse reaction related to renal function was serum creatinine increases, the majority of which were transient and reversible (see section 4.8). 
Najpogosteje poročani neželeni učinek, povezan z delovanjem ledvic, je bil povečanje kreatinina v serumu, ki je bil v večini primerov prehoden in reverzibilen (glejte poglavje 4.8).
Further evaluation of patients who had renal-related adverse events showed that most had serum creatinine changes of ≤ 0.5 mg/dL from baseline. 
Dodatne ocene bolnikov, ki so imeli z ledvicami povezane neželene učinke, so pokazale, da se je večini kreatinin v serumu spremenil za ≤ 0,5 mg/dl v primerjavi z izhodiščem.
Dapagliflozin may add to the diuretic effect of thiazide and loop diuretics and may increase the risk of dehydration and hypotension (see section 4.4). 
Dapagliflozin lahko prispeva k diuretičnemu učinku tiazidnih diuretikov ter diuretikov zanke in lahko poveča tveganje za pojav dehidracije ter hipotenzije (glejte poglavje 4.4).
In particular, if you are following a diabetic weight control diet, continue to follow it while you are taking Forxiga. 
Še zlasti, če se držite diabetične diete za obvladovanje telesne mase, nadaljujte z dieto tudi med jemanjem zdravila Forxiga.
At 24 weeks, reductions in serum uric acid concentrations ranged from -48.3 to -18.3 micromoles/l (-0.87 to -0.33 mg/dl). 
Po 24 tednih je zmanjšanje koncentracije sečne kisline v serumu segalo od -48,3 do -18,3 mikromolov/l (-0,87 do -0,33 mg/dl).
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. 
Če vam je zdravnik povedal, da ne prenašate nekaterih sladkorjev, se posvetujte z zdravnikom pred jemanjem tega zdravila.
Most infections were mild to moderate, and subjects responded to an initial course of standard treatment and rarely resulted in discontinuation from dapagliflozin treatment. 
Večina okužb je bila blagih do zmernih in preiskovanci so se odzvali na začetno standardno zdravljenje in okužbe so le redko povzročile prekinitev zdravljenja z dapagliflozinom.
• changes in the amount of red blood cells in your blood (shown in tests) 
• spremenjena količina rdečih krvnih celic v vaši krvi (to se pokaže v preiskavah)
Patients who may be at higher risk of DKA include patients with a low beta-cell function reserve (e.g. type 2 diabetes patients with low C-peptide or latent autoimmune diabetes in adults (LADA) or patients with a history of pancreatitis), patients with conditions that lead to restricted food intake or severe dehydration, patients for whom insulin doses are reduced and patients with increased insulin requirements due to acute medical illness, surgery or alcohol abuse. 
Med bolniki s potencialno večjim tveganjem za DKA so bolniki z majhno funkcijsko rezervo celic beta (npr. bolniki s sladkorno boleznijo tipa 2 z nizko vrednostjo C-peptida ali latentno avtoimunsko sladkorno boleznijo odraslih (LADA - latent autoimmune diabetes in adults) ali bolniki z anamnezo pankreatitisa), bolniki z boleznimi, ki zmanjšajo uživanje hrane ali povzročijo hudo dehidracijo, bolniki po zmanjšanju odmerka insulina in bolniki s povečano potrebo po insulinu zaradi akutne bolezni, kirurškega posega ali zlorabe alkohola.
Dapagliflozin 3-O-glucuronide or other metabolites do not contribute to the glucose-lowering effects. 
Dapagliflozin-3-O-glukuronid ali drugi presnovki ne prispevajo k učinkom zmanjšanja vrednosti glukoze.
In a separate study of pre- and postnatal development, maternal rats were dosed from gestation day 6 through postnatal day 21, and pups were indirectly exposed in utero and throughout lactation. 
V ločeni študiji pre- in postnatalnega razvoja so podganjim samicam-materam odmerjali to zdravilo od 6. dne gestacije do 21. postnatalnega dneva; mladiči so bili posredno izpostavljeni in utero in med obdobjem dojenja.
During clinical trials, the overall proportion of subjects with malignant or unspecified tumours was similar between those treated with dapagliflozin (1.50%) and placebo/comparator (1.50%), and there was no carcinogenicity or mutagenicity signal in animal data (see section 5.3). 
Med kliničnimi preskušanji je bil celotni delež oseb z malignimi ali nespecificiranimi tumorji med tistimi, ki so prejemali dapagliflozin (1,50 %) in tistimi, ki so prejemali placebo/primerjalno zdravilo (1,50 %) podoben in podatki na živalih niso pokazali signalov kancerogenosti ali mutagenosti (glejte poglavje 5.3).
In male and female rats, dapagliflozin showed no effects on fertility at any dose tested. 
Pri podganjih samcih in samicah dapagliflozin ni pokazal učinkov na plodnost pri nobenem od preskušanih odmerkov.
Rates of adverse events including dehydration or hypotension were similar to placebo, and there were no clinically meaningful dose-related changes in laboratory parameters, including serum electrolytes and biomarkers of renal function. 
Deleži neželenih dogodkov, vključujoč dehidracijo ali hipotenzijo, so bili podobni kot pri placebu in klinično pomembnih, z odmerkom povezanih sprememb laboratorijskih parametrov, vključno z elektroliti v serumu in biološkimi označevalci delovanja ledvic, niso ugotovili.
• if you have an increase in the amount of red blood cells in your blood, seen in tests. 
• če imate povečano količino rdečih krvnih celic v vaši krvi, kar se določi s preiskavo.
There are insufficient data to draw conclusions regarding exposure in patients > 70 years old. 
Za sklepanje o izpostavljenosti bolnikov, starejših od 70 let, ni dovolj podatkov.
When considering the cases of tumours occurring in the different organ systems, the relative risk associated with dapagliflozin was above 1 for some tumours (bladder, prostate, breast) and below 1 for others (e.g. blood and lymphatic, ovary, renal tract), not resulting in an overall increased tumour risk associated with dapagliflozin. 
Pri obravnavi primerov pojava tumorjev v različnih organskih sistemih, je bilo relativno tveganje povezano z dapagliflozinom večje od 1 za nekatere tumorje (mehurja, prostate, dojke) in manjše od 1 za ostale (npr. krvi in limfatičnega sistema, jajčnikov, urinarnega trakta), kar ni vodilo v celokupno povečanje tveganja za pojav tumorja v povezavi z dapagliflozinom.
• if you experience rapid weight loss, feeling sick or being sick, stomach pain, excessive thirst, fast and deep breathing, confusion, unusual sleepiness or tiredness, a sweet smell to your breath, a sweet or metallic taste in your mouth, or a different odour to your urine or sweat, contact a doctor or the nearest hospital straight away. 
• če se vam pojavijo hitra izguba telesne mase, slabost ali bruhanje, bolečine v trebuhu, prekomerna žeja, hitro in globoko dihanje, zmedenost, neobičajna zaspanost ali utrujenost, sladek vonj izdihanega zraka, sladek ali kovinski okus v ustih ali spremenjen vonj urina ali znoja, se takoj posvetujte z zdravnikom ali pojdite v najbližjo bolnišnico.
These are signs of dehydration: - very dry or sticky mouth, feeling very thirsty - feeling very sleepy or tired - passing little or no water (urine) - fast heart beat. 
Znaki dehidracije so: - zelo suha ali lepljiva usta, občutek hude žeje - izrazita zaspanost ali utrujenost - odvajanje malo ali nič vode (urina) - hitro bitje srca.
Adverse drug reactions related to increased creatinine were grouped (e.g. decreased renal creatinine clearance, renal impairment, increased blood creatinine and decreased glomerular filtration rate). 
Neželene učinke, povezane z zvišanjem kreatinina, so združili v skupino (npr. zmanjšan ledvični očistek kreatinina, okvara ledvic, zvišan kreatinin v krvi in zmanjšana hitrost glomerularne filtracije).
The frequency of minor episodes of hypoglycaemia was similar between treatment groups, including placebo, with the exceptions of studies with add-on sulphonylurea (SU) and add-on insulin therapies. 
Pogostost blage hipoglikemije je bila med skupinami podobna, vključno s placebom, z izjemo študij zdravljenja z dodatkom sulfonilsečnin (SU) in dodatkom insulina.
Dapagliflozin does not impair normal endogenous glucose production in response to hypoglycaemia. 
Dapagliflozin ne poslabša normalnega endogenega nastajanja glukoze kot odziva na hipoglikemijo.
The mean total systemic clearance of dapagliflozin administered intravenously was 207 ml/min. 
Povprečni skupni sistemski očistek dapagliflozina, danega intravensko, je bil 207 ml/min.
In a pre-specified pooled analysis of 13 placebo-controlled studies, 2,360 subjects were treated with dapagliflozin 10 mg and 2,295 were treated with placebo. 
V vnaprej specificirani kumulativni analizi 13, s placebom kontroliranih študij, je 2.360 preiskovancev bilo zdravljenih z 10 mg dapagliflozina in 2.295 je prejemalo placebo.
• if you have a liver problem - your doctor may start you on a lower dose. 
• če imate težave z jetri - zdravnik bo pri vas morda začel zdravljenje z manjšim odmerkom.
You should stop taking this medicine if you become pregnant, since it is not recommended during the second and third trimesters of pregnancy. 
Če zanosite, morate prekiniti zdravljenje z zdravilom Forxiga, saj uporaba zdravila v drugem in tretjem trimesečju nosečnosti ni priporočljiva.